- Home
- Companies
- MedChemExpress LLC (MCE)
- Products
- MedChemExpress - Model Doxifluridine - ...
MedChemExpress - Model Doxifluridine -3094-09-5
Doxifluridine has anticancer activity. Doxifluidine is a 5-FU prodrug. Doxifluridine is a thymidine synthase inhibitor. Doxifluridine can enhance tumor inhibition by synergizing with a variety of drugs[1][2][3].MCE products for research use only. We do not sell to patients.
Doxifluridine
MCE China：Doxifluridine
Brand：MedChemExpress (MCE)
Cat. No.HY-B0021
CAS：3094-09-5
Synonyms：Ro 21-9738; 5-Fluoro-5'-deoxyuridine; 5'-DFUR
Purity：99.91%
Storage：Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Shipping：Room temperature in continental US; may vary elsewhere.
Description：Doxifluridine has anticancer activity. Doxifluidine is a 5-FU prodrug. Doxifluridine is a thymidine synthase inhibitor. Doxifluridine can enhance tumor inhibition by synergizing with a variety of drugs.
In Vitro：Doxifluridine (1-10 μM) inhibits angiogenesis by significantly inhibiting the expression of VEGF in FU-MMT-1 cells[1]. Doxifluridine (1-100 μM) slightly increases the expression of TSP-1 at low dose (1 μM) and inhibits the expression of TSP-1 at high dose (100 μM) in FU-MMT-1 cells[1]. Doxifluridine (100 μM) inhibits cell proliferation in HUVEC cells[1].
In Vivo：Doxifluridine (61.55 mg/kg; Intragastric administration; Single dose) has anticancer activity in BALB ⁄ cA Jcl-nu mice, and can significantly enhance anticancer activity in combination with TNP-470 (HY-101932)[1]. Doxifluridine (200 mg/kg; Intraperitoneal injection; Single dose) can inhibit thymidine synthase activity in DMH-induced colon cancer mice[2].
Hot selling product：Eravacycline (dihydrochloride) | Methicillin (sodium salt) | Ginkgolic Acid | Guselkumab | SCH-23390 (hydrochloride) | Belumosudil | Colcemid | AU-15330 | Tetracycline | DMH-1
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides
References：
[1]. Naganuma Y, et al. Metronomic doxifluridine chemotherapy combined with the anti-angiogenic agent TNP-470 inhibits the growth of human uterine carcinosarcoma xenografts. Cancer Sci. 2011 Aug;102(8):1545-52. [Content Brief]
[2]. Berne M, et al. Inhibition of thymidylate synthase after administration of doxifluridine in a transplantable colon carcinoma in the rat. Cancer Invest. 1988;6(4):377-83. [Content Brief]
[3]. Di Bartolomeo M, et al. Integrated treatment with doxifluridine and radiotherapy in recurrent or primary unresectable rectal cancer. A feasibility study. Tumori. 1999 May-Jun;85(3):211-3. [Content Brief]
Brand introduction:
• MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world；
• More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas；
• The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects；
• Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services；
• It has a professional experimental center and strict quality control and verification system；
• Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products；
• The biological activity of the products has been verified by the experiments of customers in various countries；
• A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers；
• Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world；
• It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。